UTTR1147A
Sponsors
Genentech, Inc.
Conditions
COVID-19 PneumoniaCrohn's DiseaseNeuropathic Diabetic Foot UlcersUlcerative Colitis
Phase 1
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
CompletedNCT02749630
Start: 2016-04-11End: 2020-02-19Updated: 2020-10-30
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
CompletedNCT02833389
Start: 2016-11-14End: 2018-11-12Updated: 2018-11-21
Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
CompletedNCT03558152
Start: 2018-10-26End: 2021-12-15Updated: 2023-04-14
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
TerminatedNCT03650413
Start: 2019-01-14End: 2022-07-12Updated: 2023-09-29
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
CompletedNCT04386616
Start: 2020-06-02End: 2021-02-12Updated: 2022-01-10